Metrics details. Human Papillomavirus HPV infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts GW.
Two prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HPV type 16 and 18 infection and a quadrivalent vaccine targeting HPV 6, 11, 16, and In France, HPV vaccination is recommended in year-old girls with a catch-up for girls aged Compared to the quadrivalent vaccine, the proportion of additional cases potentially prevented by the nonavalent vaccine was 9.
Peer Review reports. Human Papillomavirus HPV infection is known to be associated with a number of conditions including cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts GW [ 1 - 5 ]. Two prophylactic vaccines using L1 virus-like particles VLP are available and widely marketed internationally.
These vaccines were primarily developed with the aim of reducing HPV-related cervical cancer. In France, HPV vaccination is recommended in year-old girls with a catch-up for girls aged [ 9 ].
Serrano et al. These studies have shown that a proportion of HPV-related lesions were not targeted by currently available vaccines. Histological specimens of invasive cervical cancers HPV prevalence, For each condition, HPV genotype distributions were used to assess the potential impact of the quadrivalent and the nonavalent vaccines in France.
